The clinical performance is complex and often involves multi-systematic stress. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a comprehensive assessment platform that combines clinical performance, imaging, laboratory testing and pathological activation.
A team of authoritative experts at home and abroad can assist in providing accurate diagnosis and treatment programs. Individualised development of treatment and management of low-protein HPIs, usually including drug therapy, rehabilitation interventions, and regular follow-up to multiple-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the course of the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of low HL co-protein. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.